glp 1 hims The GLP-1 legal battle is heating up. Novo Nordisk sued & Hers after the telehealth company announced plans to sell a compounded oral GLP-1 pill positioned as a lower-cost alternative to Hims & Hers Just Lost

He has followed the stock markets right from his early college days

Pharmacokinetic DDIs of GLP-1 RAs and a Dual GLP-1/GIP RA Drug-Metabolizing Enzyme-and Transporter-Mediated DDIs GLP-1 RAs and a dual GLP-1/GIP RA are now approved for the treatment of type 2 diabetes and obesity, with patients frequently managing coexisting metabolic diseases that require additional medications.137 Consequently, using multiple medications can result in DDIs, often leading to adverse drug reactions, making it crucial to assess the DDI potential.138 To date, there are limited data on clinically significant metabolic enzyme- or transporter-mediated DDIs involving GLP-1 RAs and a dual GLP-1/GIP RA

Under the terms of the agreement, Merck will gain exclusive rights to develop and market HS-10270 outside of China, while Hansoh Pharma will retain exclusive rights for its development and commercialization within China

But they work through different hormonal pathways